Roberto M. Lemoli

15.9k total citations · 2 hit papers
239 papers, 7.7k citations indexed

About

Roberto M. Lemoli is a scholar working on Hematology, Immunology and Molecular Biology. According to data from OpenAlex, Roberto M. Lemoli has authored 239 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 145 papers in Hematology, 71 papers in Immunology and 55 papers in Molecular Biology. Recurrent topics in Roberto M. Lemoli's work include Hematopoietic Stem Cell Transplantation (73 papers), Acute Myeloid Leukemia Research (68 papers) and Multiple Myeloma Research and Treatments (48 papers). Roberto M. Lemoli is often cited by papers focused on Hematopoietic Stem Cell Transplantation (73 papers), Acute Myeloid Leukemia Research (68 papers) and Multiple Myeloma Research and Treatments (48 papers). Roberto M. Lemoli collaborates with scholars based in Italy, United States and Germany. Roberto M. Lemoli's co-authors include Antonio Curti, S Tura, Michele Baccarani, Davide Ferrari, Francesco Di Virgilio, Valentina Salvestrini, Marco Idzko, Miriam Fogli, Elena Adinolfi and Cinzia Pizzirani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Roberto M. Lemoli

230 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The P2X7 Receptor: A Key Player in IL-1 Processing and Release

2006 880 citations Davide Ferrari, Roberto M. Lemoli et al. The Journal of Immunology profile →
Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients

2023 71 citations Małgorzata Mikulska, Chiara Sepulcri et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Roberto M. Lemoli Italy	48	3.1k	2.9k	2.1k	1.8k	972	239	7.7k
Antonio Curti Italy	36	2.4k 0.8×	1.4k 0.5×	1.3k 0.6×	1.2k 0.7×	901 0.9×	156	5.2k
Paul J. Orchard United States	44	2.5k 0.8×	2.4k 0.8×	3.7k 1.8×	2.6k 1.4×	232 0.2×	224	10.5k
Silvia Deaglio Italy	56	4.5k 1.5×	1.3k 0.4×	3.1k 1.5×	2.6k 1.4×	3.7k 3.8×	226	11.4k
George H. Caughey United States	59	5.3k 1.7×	1.1k 0.4×	2.7k 1.3×	931 0.5×	244 0.3×	134	10.1k
H. Terence Cook United Kingdom	48	6.5k 2.1×	1.3k 0.4×	2.2k 1.1×	391 0.2×	350 0.4×	122	9.6k
Akio Ohta Japan	22	2.8k 0.9×	1.3k 0.4×	1.2k 0.6×	915 0.5×	1.4k 1.4×	81	5.5k
Nicholas D. Huntington Australia	51	7.0k 2.3×	704 0.2×	2.5k 1.2×	3.0k 1.6×	252 0.3×	111	10.1k
Armand Bensussan France	59	6.9k 2.2×	467 0.2×	2.1k 1.0×	2.2k 1.2×	404 0.4×	347	11.8k
Katsuhiko Ishihara Japan	34	2.4k 0.8×	387 0.1×	2.1k 1.0×	1.6k 0.9×	577 0.6×	81	5.8k
Ada Funaro Italy	35	1.6k 0.5×	473 0.2×	1.2k 0.6×	782 0.4×	1.9k 2.0×	94	5.0k

Countries citing papers authored by Roberto M. Lemoli

Since Specialization

Citations

This map shows the geographic impact of Roberto M. Lemoli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roberto M. Lemoli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roberto M. Lemoli more than expected).

Fields of papers citing papers by Roberto M. Lemoli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roberto M. Lemoli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roberto M. Lemoli. The network helps show where Roberto M. Lemoli may publish in the future.

Co-authorship network of co-authors of Roberto M. Lemoli

This figure shows the co-authorship network connecting the top 25 collaborators of Roberto M. Lemoli. A scholar is included among the top collaborators of Roberto M. Lemoli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roberto M. Lemoli. Roberto M. Lemoli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caffa, Irene, Tommaso Bonfiglio, Ana Guijarro, et al.. (2025). Prognostic Frailty-Based Determinants of Long-Term Mortality in Older Patients with Newly Diagnosed Multiple Myeloma. Cancers. 17(5). 789–789.

Guolo, Fabio, Francesca Riccardi, C Perrone, et al.. (2025). The protective role of HCWs communication for the distress of newly diagnosed people with leukemia and lymphoma. PEC Innovation. 7. 100439–100439.

Minetto, Paola, Marco Greppi, Silvia Pesce, et al.. (2023). Harnessing Immune Response in Acute Myeloid Leukemia. Journal of Clinical Medicine. 12(18). 5824–5824. 8 indexed citations

Meazza, Raffaella, Loredana Ruggeri, Fabio Guolo, et al.. (2023). Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire. Frontiers in Immunology. 14. 1111419–1111419. 7 indexed citations

Lemoli, Roberto M., Pau Montesinos, & Akriti Jain. (2023). Real-world experience with CPX-351 in high-risk acute myeloid leukemia. Critical Reviews in Oncology/Hematology. 185. 103984–103984. 9 indexed citations

Mikulska, Małgorzata, Chiara Sepulcri, Chiara Dentone, et al.. (2023). Triple Combination Therapy With 2 Antivirals and Monoclonal Antibodies for Persistent or Relapsed Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients. Clinical Infectious Diseases. 77(2). 280–286. 71 indexed citations breakdown →

Pollyea, Daniel A., Courtney D. DiNardo, Martha Arellano, et al.. (2020). Results of Venetoclax and Azacitidine Combination in Chemotherapy Ineligible Untreated Patients with Acute Myeloid Leukemia with IDH 1/2 Mutations. Blood. 136(Supplement 1). 5–7. 27 indexed citations

Minetto, Paola, Fabio Guolo, Marino Clavio, et al.. (2017). Patient and Therapy-Related Factors Affecting the Toxicity of Pegylated-Asparaginase for the Treatment of Adult Acute Lymphoblastic Leukemia. Blood. 130. 1297–1297. 3 indexed citations

Minetto, Paola, Debora Soncini, Antonia Cagnetta, et al.. (2017). Glutamine-Dependence Targeting By Asparaginase Significantly Increases Anti-Myeloma Activity of Proteasome Inhibitors. Blood. 130. 1796–1796. 1 indexed citations

10.

Martino, Massimo, Roberto M. Lemoli, Corrado Girmenia, et al.. (2016). Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. Bone Marrow Transplantation. 51(8). 1032–1040. 16 indexed citations

11.

Minetto, Paola, Fabio Guolo, Marino Clavio, et al.. (2015). Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes. Leukemia Research. 39(8). 866–873. 11 indexed citations

12.

Ciciarello, Marilena, Roberta Zini, Lara Rossi, et al.. (2012). Extracellular Purines Promote the Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells to the Osteogenic and Adipogenic Lineages. Stem Cells and Development. 22(7). 1097–1111. 95 indexed citations

13.

Lemoli, Roberto M., Valentina Salvestrini, Elisa Bianchi, et al.. (2009). Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34− cell population with intrinsic resistance to imatinib. Blood. 114(25). 5191–5200. 58 indexed citations

14.

Lemoli, Roberto M., et al.. (2007). The P2X7 receptor: a key player in IL-1 processing and release. The Journal of Immunology. 179(12). 8569–8569. 27 indexed citations

15.

Tazzari, Pier Luigi, Letizia Polito, Andrea Bolognesi, et al.. (2001). Immunotoxins Containing Recombinant Anti-CTLA-4 Single-Chain Fragment Variable Antibodies and Saporin: In Vitro Results and In Vivo Effects in an Acute Rejection Model. The Journal of Immunology. 167(8). 4222–4229. 33 indexed citations

16.

Curti, Antonio, Miriam Fogli, Marina Ratta, S Tura, & Roberto M. Lemoli. (2001). Stem Cell Factor and FLT3-Ligand Are Strictly Required to Sustain the Long-Term Expansion of Primitive CD34+DR− Dendritic Cell Precursors. The Journal of Immunology. 166(2). 848–854. 51 indexed citations

17.

Nicola, Massimo Di & Roberto M. Lemoli. (2000). Dendritic cells: specialized antigen presenting cells.. PubMed. 85(2). 202–7. 18 indexed citations

18.

Rizzi, Simonetta, Marina Ratta, Alessandra Fortuna, et al.. (1997). Pharmacological purging of minimal residual disease from peripheral blood stem cell collections of acute myeloblastic leukemia patients: preclinical studies.. PubMed. 25(12). 1261–9. 20 indexed citations

19.

Lemoli, Roberto M., Michèle Cavo, & Alessandra Fortuna. (1996). Concomitant Mobilization of Plasma Cells and Hematopoietic Progenitors into Peripheral Blood of Patients with Multiple Myeloma. Journal of Hematotherapy. 5(4). 339–349. 19 indexed citations

20.

Lemoli, Roberto M., Giuseppe Visani, Simonetta Rizzi, et al.. (1988). Long-term cryopreservation of autologous bone marrow: analysis of granulocyte-macrophage progenitor (CFU-GM) viability in 31 samples stored more than 48 months.. PubMed. 73(2). 101–4. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact